Fever in immunocompromised patients

Authors

Keywords:

fever, immunocompromised host, immune system.

Abstract

Introduction: Fever is a marker of infectious and inflammatory diseases that is caused by an innate immune response and by different mediations between molecular markers. In the immunocompromised patient, one or more immunological mechanisms may be altered because the immune response may be compromised, and fever may denote a serious underlying disease state. An exploratory search was conducted in the PubMed/Medline, Scopus, and Scielo databases between September and October 2022. The terms fever immunocompromised patients, treatment, and immune system. A total of 41 scientific articles with different epidemiological designs were selected.
Objective: To describe aspects related to the pathophysiology of fever, management of the presence of fever in patients with Human Immunodeficiency Virus and Acquired Immunodeficiency Syndrome, as well as in patients who have received solid organ transplants and hematopoietic transplants, neutropenic patients and patients treated with corticosteroids and biological therapy.
Developing: The approach to the immunocompromised patient with fever includes fundamental aspects such as an adequate history and physical examination, as well as diagnostic tests aimed at establishing the cause of the fever. In these patients, infections play a leading role and early intervention is essential to impact morbidity and mortality.
Conclusions: The immunocompromised patient with the presence of fever presents a challenging panorama for his/her comprehensive medical approach. Among other aspects, it is relevant to consider the type and duration of immunosuppression, as well as the risk factors, to guide diagnoses and treatments.


Downloads

Download data is not yet available.

References

1. O'Grady NP, Barie PS, Bartlett JG, Bleck T, Carroll K, Kalil AC, et al. American College of Critical Care Medicine; Infectious Diseases Society of America. Guidelines for evaluation of new fever in critically ill adult patients: 2008 update from the American College of Critical Care Medicine and the Infectious Diseases Society of America. Crit Care Med. 2008;36(4):1330-49. DOI: 10.1097/CCM.0b013e318169eda9

2. Keck JM, Wingler MJB, Cretella DA, Vijayvargiya P, Wagner JL, Barber KE, et al. Approach to fever in patients with neutropenia: a review of diagnosis and management. Ther Adv Infect Dis. 2022;26(9):20499361221138346. DOI: 10.1177/20499361221138346

3. Hampton T. Fever Induces a Molecular Homing Response in Immune Cells During Infection. JAMA. 2019;321(17):1657-1658. DOI: 10.1001/jama.2019.4475

4. Siggins MK, MacLennan CA. An adsorption method to prepare specific antibody-depleted normal human serum as a source of complement for human serum bactericidal assays for Salmonella. Vaccine. 2021;39(51):7503-7509. DOI: 10.1016/j.vaccine.2021.10.023

5. Dolan JR. Re-Claiming Adrien Certes (1835-1903), Pioneer Deep-Sea Microbiologist, as a Protistologist. Protist. 2020;171(6):125772. DOI: 10.1016/j.protis.2020.125772

6. Drewry A, Mohr NM. Temperature Management in the ICU. Crit Care Med. 2022;50(7):1138-1147. DOI:10.1097/CCM.0000000000005556

7. Wright WF, Mulders-Manders CM, Auwaerter PG, Bleeker-Rovers CP. Fever of Unknown Origin (FUO) - A Call for New Research Standards and Updated Clinical Management. Am J Med. 2022;135(2):173-8. DOI: 10.1016/j.amjmed.2021.07.038

8. Walter EJ, Hanna-Jumma S, Carraretto M, Forni L. The pathophysiological basis and consequences of fever. Crit Care. 2016;20(1):200. DOI: 10.1186/s13054-016-1375-5

9. Pedaci M, Londoni C, Bertè R, Buscarini E. A stubborn fever. Dig Liver Dis. 2022;54(10):1444-5. DOI: 10.1016/j.dld.2021.09.013

10. Pincus D. Regulation of Hsf1 and the Heat Shock Response. Adv Exp Med Biol. 2020; 1243:41-50. DOI: 10.1007/978-3-030-40204-4_3

11. Wright WF, Auwaerter PG. Fever and Fever of Unknown Origin: Review, Recent Advances, and Lingering Dogma. Open Forum Infect Dis. 2020;7(5):ofaa132. DOI: 10.1093/ofid/ofaa132

12. Xu J, Ma C, Hua M, Li J, Xiang Z, Wu J. CNS and CNS diseases in relation to their immune system. Front Immunol. 2022;13:1063928. DOI: 10.3389/fimmu.2022.1063928

13. Osterhout JA, Kapoor V, Eichhorn SW, Vaughn E, Moore JD, Liu D, et al. A preoptic neuronal population controls fever and appetite during sickness. Nature. 2022; 606(7916):937-44. DOI: 10.1038/s41586-022-04793-z

14. Carnevale L, Perrotta M, Lembo G. A Focused Review of Neural Recording and Stimulation Techniques With Immune-Modulatory Targets. Front Immunol. 2021; 12:689344. DOI:10.3389/fimmu.2021.689344

15. Bonadio W. Commentary on New Guidelines for the Evaluation and Management of the Febrile Young Infant. Pediatrics. 2022;149(1):e2021055005A. DOI: 10.1542/peds.2021-055005A

16. Hasbun R. Progress and Challenges in Bacterial Meningitis: A Review. JAMA. 2022;328(21):2147-2154. DOI:10.1001/jama.2022.20521

17. Tuano KS, Seth N, Chinen J. Secondary immunodeficiencies: An overview. Ann Allergy Asthma Immunol. 2021;127(6):617-626. DOI: 10.1016/j.anai.2021.08.413

18. Vishnevetsky A, Anand P. Approach to Neurologic Complications in the Immunocompromised Patient. Semin Neurol. 2021;41(5):554-71. DOI: 10.1055/s-0041-1733795

19. Hajiabdolbaghi M, Ataeinia B, Ghadimi F, SeyedAlinaghi S, Badie BM, Dadras O, et al. Bone Marrow Aspiration/Biopsy in the Evaluation of Fever of Unknown Origin in Patients with AIDS. Infect Disord Drug Targets. 2021;21(3):394-8. DOI: 10.2174/1871526520666200705212903

20. Roberts MB, Fishman JA. Immunosuppressive Agents and Infectious Risk in Transplantation: Managing the "Net State of Immunosuppression". Clin Infect Dis. 2021;73(7):e1302-e1317. DOI:10.1093/cid/ciaa1189

21. Lozano F, Torre-Cisneros J, Santos J, León E, Domínguez A, Montesdeoca M, et al. Impact of highly active antiretroviral therapy on fever of unknown origin in HIV-infected patients. Eur J Clin Microbiol Infect Dis. 2002;21(2):137-9. DOI: 10.1007/s10096-001-0676-y

22. Haidar G, Singh N. Fever of Unknown Origin. N Engl J Med. 2022;386(5):463-477. DOI: 10.1056/NEJMra2111003

23. Sepkowitz KA, Telzak EE, Carrow M, Armstrong D. Fever among outpatients with advanced human immunodeficiency virus infection. Arch Intern Med. 1993 [acceso: 01/07/2023];153(16):1909-12. Disponible en: https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/617709

24. Ramos-Rincon JM, Menchi-Elanzi M, Pinargote-Celorio H, Mayoral A, González-Alcaide G, de Mendoza C, et al. Trends in hospitalizations and deaths in HIV-infected patients in Spain over two decades. AIDS. 2022;36(2):249-56. DOI: 10.1097/QAD.0000000000003105

25. Hajiabdolbaghi M, Ataeinia B, Ghadimi F, SeyedAlinaghi S, Badie BM, Dadras O, et al. Bone Marrow Aspiration/Biopsy in the Evaluation of Fever of Unknown Origin in Patients with AIDS. Infect Disord Drug Targets. 2021;21(3):394-398. DOI: 10.2174/1871526520666200705212903

26. Rajasingham R, Govender NP, Jordan A, Loyse A, Shroufi A, Denning DW, et al. The global burden of HIV-associated cryptococcal infection in adults in 2020: a modelling analysis. Lancet Infect Dis. 2022;22(12):1748-55. DOI: 10.1016/S1473-3099(22)00499-6

27. Temfack E, Rim JJB, Spijker R, Loyse A, Chiller T, Pappas PG, et al. Cryptococcal Antigen in Serum and Cerebrospinal Fluid for Detecting Cryptococcal Meningitis in Adults Living With Human Immunodeficiency Virus: Systematic Review and Meta-Analysis of Diagnostic Test Accuracy Studies. Clin Infect Dis. 2021;72(7):1268-1278. DOI: 10.1093/cid/ciaa1243

28. Rajasingham R, Wake RM, Beyene T, Katende A, Letang E, Boulware DR. Cryptococcal Meningitis Diagnostics and Screening in the Era of Point-of-Care Laboratory Testing. J Clin Microbiol. 2019;57(1):e01238-18. DOI: 10.1128/JCM.01238-18

29. Harjani RG, Hinduja RH, Iyer AK. Intracranial lymphoma in human immunodeficiency virus-infected patients: A diagnostic dilemma?. Indian J Sex Transm Dis AIDS. 2022;43(1):82-84. doi:10.4103/ijstd.ijstd_10_21

30. Arora N, Kotwani S, Chhabra M, H M. Hemorrhagic Lesions in the Central Nervous System: Toxoplasmosis in a Person Living With Human Immunodeficiency Virus Infection and Acquired Immunodeficiency Syndrome. Cureus. 2022;14(5):e24827. DOI: 10.7759/cureus.24827

31. Ison MG. Transplant infectious disease: Renewing a home for TID research. Transpl Infect Dis. 2022;24(1):e13760. DOI: 10.1111/tid.13760

32. Dettori M, Riccardi N, Canetti D, Antonello RM, Piana AF, Palmieri A, et al. Infections in lung transplanted patients: A review. Pulmonology. 2022:S2531-0437(22)00118-0. DOI: 10.1016/j.pulmoe.2022.04.010

33. Mrzljak A, Novak R, Pandak N, Tabain I, Franusic L, Barbic L, et al. Emerging and neglected zoonoses in transplant population. World J Transplant. 2020;10(3):47-63. DOI: 10.5500/wjt.v10.i3.47

34. Olnes MJ. Immune Therapies for Hematologic Malignancies. Cancers (Basel). 2021;13(2):295. Published 2021 Jan 15. DOI:10.3390/cancers13020295

35. Klastersky J, de Naurois J, Rolston K, Rapoport B, Maschmeyer G, Aapro M, et al. ESMO Guidelines Committee. Management of febrile neutropaenia: ESMO Clinical Practice Guidelines. Ann Oncol. 2016;27(suppl 5):v111-v118. DOI: 10.1093/annonc/mdw325

36. Heinz WJ, Buchheidt D, Christopeit M, von Lilienfeld-Toal M, Cornely OA, Einsele H, et al. Diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). Ann Hematol. 2017;96(11):1775-92. DOI.org/10.1007/s00277-017-3098-3

37. Malpica L, Moll S. Practical approach to monitoring and prevention of infectious complications associated with systemic corticosteroids, antimetabolites, cyclosporine, and cyclophosphamide in nonmalignant hematologic diseases. Hematology Am Soc Hematol Educ Program. 2020;2020(1):319-27. DOI: 10.1182/hematology.2020000116

38. Shobha V, Chandrashekara S, Rao V, Desai A, Jois R, Dharmanand BG, et al. Biologics and risk of tuberculosis in autoimmune rheumatic diseases: A real-world clinical experience from India. Int J Rheum Dis. 2019;22(2):280-287. DOI: 10.1111/1756-185X.13376

39. Malpica L, Moll S. Practical approach to monitoring and prevention of infectious complications associated with systemic corticosteroids, antimetabolites, cyclosporine, and cyclophosphamide in nonmalignant hematologic diseases. Hematology Am Soc Hematol Educ Program. 2020;2020(1):319-327. DOI:10.1182/hematology.2020000116

40. Takabayashi K, Ando F, Ikeda K, Nakajima H, Hanaoka H, Suzuki T. Incidence of opportunistic infections in patients with rheumatoid arthritis treated with different molecular-targeted drugs: A population-based retrospective cohort study. Mod Rheumatol. 2022:roac133. DOI: 10.1093/mr/roac133

41. Voelker R. Biologic Treatment Approved for Rare Blood Disorders. JAMA. 2020;324(17):1715. DOI:10.1001/jama.2020.21140

Downloads

Published

2023-12-21

How to Cite

1.
Weir-Restrepo D, Zuluaga-Gómez M, Valverde-Legarda AE, Ardila CM. Fever in immunocompromised patients. Rev Cubana Med Milit [Internet]. 2023 Dec. 21 [cited 2025 May 23];53(1):e024017871. Available from: https://revmedmilitar.sld.cu/index.php/mil/article/view/17871

Issue

Vol. 53 No. 1 (2024): January - March

Section

Review Article

License

Authors who have publications with this Journal accept the following terms:

  • The authors will retain their copyright and guarantee the Journal the right of first publication of their work, which will simultaneously be subject to the Creative Commons Attribution License. The content presented here can be shared, copied and redistributed in any medium or format; Can be adapted, remixed, transformed or created from the material, using the following terms: Attribution (giving appropriate credit to the work, providing a link to the license, and indicating if changes have been made); non-commercial (you cannot use the material for commercial purposes) and share-alike (if you remix, transform or create new material from this work, you can distribute your contribution as long as you use the same license as the original work).
  • The authors may adopt other non-exclusive license agreements for the distribution of the published version of the work (for example: depositing it in an institutional electronic archive or publishing it in a monographic volume) as long as the initial publication in this Journal is indicated.
  • Authors are allowed and recommended to disseminate their work through the Internet (e.g., in institutional electronic archives or on their website) before and during the submission process, which can produce interesting exchanges and increase citations. of the published work.